MedTrace Logo

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01815450 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2015-02-02

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BLI1100

BLI1100 topical cream

DRUG

BLI1100 - modified formulation

BLI1100 topical cream

DRUG

Placebo

Placebo topical cream

Sponsors & Collaborators

  • Braintree Laboratories

    lead INDUSTRY

Principal Investigators

  • John McGowan, MPH · Braintree Laboratories, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01815450 on ClinicalTrials.gov